[go: up one dir, main page]

HN2008001374A - Compuestos de cinamida policiclicos - Google Patents

Compuestos de cinamida policiclicos

Info

Publication number
HN2008001374A
HN2008001374A HN2008001374A HN2008001374A HN2008001374A HN 2008001374 A HN2008001374 A HN 2008001374A HN 2008001374 A HN2008001374 A HN 2008001374A HN 2008001374 A HN2008001374 A HN 2008001374A HN 2008001374 A HN2008001374 A HN 2008001374A
Authority
HN
Honduras
Prior art keywords
group
similar
polymycinal
cinamide
compounds
Prior art date
Application number
HN2008001374A
Other languages
English (en)
Inventor
Kimura Teiji
Kitazawa Noritaka
Kaneko Toshihiko
Sato Nobusaki
Kawano Koki
Ito Koichi
Doi Eriko
Takaishi Mamoru
Sasaki Takeo
Doko Takashi
Miyagawa Takehiko
Hagiwara Hiroaki
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of HN2008001374A publication Critical patent/HN2008001374A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

ESTA PATENTE SE REFIERE A UN COMPUESTO REPRESENTADO POR LA FORMULA I. O UNA SAL FARMACOLOGICAMENTE ACEPTABLE DEL MISMO , EN DONDE Ar1 REPRESENTA A UN GRUPO IMIDAZOLILO QUE PUEDE SUBSTITUIRSE POR UN GRUPO ALQUILO C1--6 O SIMILARES, Ar2 REPRESENTA UN GRUPO FENILO QUE PUEDEN SUSTITUIRSE POR UN GRUPO ALCOXI C1-6 O SIMILARES, X1 REPRESENTA UN ENLACE DOBLE O SIMILARES Y HET REPRESENTA UN GRUPO IMIDAZOLILO QUE PUEDE SUBSTITUIRSE POR UN GRUPO ALQUILO C1- 6 O SIMILARES. EL COMPUESTO O LA SAL ES EFECTIVO COMO UN AGENTE TERAPEUTICO P PROFILACTICO PARA UNA ENFERMEDAD ASOCIADA CON AB
HN2008001374A 2006-03-09 2008-09-05 Compuestos de cinamida policiclicos HN2008001374A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78051706P 2006-03-09 2006-03-09
JP2006063562 2006-03-09
US86170206P 2006-11-30 2006-11-30
JP2006322728 2006-11-30

Publications (1)

Publication Number Publication Date
HN2008001374A true HN2008001374A (es) 2011-03-15

Family

ID=38474999

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2008001374A HN2008001374A (es) 2006-03-09 2008-09-05 Compuestos de cinamida policiclicos

Country Status (15)

Country Link
EP (1) EP1992618B1 (es)
KR (1) KR101464651B1 (es)
AR (1) AR059955A1 (es)
AU (1) AU2007223158B2 (es)
CA (1) CA2643796A1 (es)
CY (1) CY1112767T1 (es)
EA (1) EA016464B1 (es)
GE (1) GEP20115139B (es)
HN (1) HN2008001374A (es)
HR (1) HRP20120174T1 (es)
IL (1) IL193770A (es)
MA (1) MA30268B1 (es)
MX (1) MX2008011221A (es)
PL (1) PL1992618T3 (es)
WO (1) WO2007102580A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335816B (en) 2004-05-26 2011-01-11 Eisai R&D Man Co Ltd Cinnamide compound
DE602005019602D1 (de) 2004-10-26 2010-04-08 Eisai R&D Man Co Ltd Amorphe form einer zimtsäureamidverbindung
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
AU2006317457B2 (en) 2005-11-24 2011-09-08 Eisai R & D Management Co., Ltd. Morpholine type cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
US7737141B2 (en) 2006-07-28 2010-06-15 Eisai R&D Management Co., Ltd. Prodrug of cinnamide compound
US8183276B2 (en) * 2007-02-08 2012-05-22 Christian Fischer Therapeutic agents
TW200848054A (en) 2007-02-28 2008-12-16 Eisai R&D Man Co Ltd Two cyclic oxomorpholine derivatives
MX2009012163A (es) 2007-05-11 2009-12-01 Hoffmann La Roche Hetarilanilinas como moduladores para beta-amiloide.
CN101809016A (zh) * 2007-06-01 2010-08-18 先灵公司 γ-分泌酶调节剂
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
JP5433418B2 (ja) * 2007-08-31 2014-03-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 多環式化合物
CA2704698A1 (en) * 2007-11-05 2009-05-14 Schering Corporation Gamma secretase modulators
US20100298372A1 (en) * 2007-12-11 2010-11-25 Schering Corporation Gamma secretase modulators
RU2527177C2 (ru) 2007-12-20 2014-08-27 Энвиво Фармасьютикалз, Инк. Четырехзамещенные бензолы
WO2009080533A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
WO2009087127A1 (en) 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Modulators for amyloid beta
ES2428716T3 (es) 2008-02-22 2013-11-11 F. Hoffmann-La Roche Ag Moduladores de beta-amiloide
WO2010025197A1 (en) * 2008-08-27 2010-03-04 Eisai R&D Management Co., Ltd. Process for preparing certain cinnamide compounds
WO2010040661A1 (en) 2008-10-09 2010-04-15 F. Hoffmann-La Roche Ag Modulators for amyloid beta
CA2742317A1 (en) * 2008-11-06 2010-05-14 Schering Corporation Gamma secretase modulators
EP2356124A1 (en) * 2008-11-06 2011-08-17 Schering Corporation Gamma secretase modulators
KR101293421B1 (ko) 2008-11-10 2013-08-05 에프. 호프만-라 로슈 아게 헤테로사이클릭 감마 분비효소 조절제
AU2009314205A1 (en) * 2008-11-13 2010-05-20 Merck Sharp & Dohme Corp. Gamma secretase modulators
TW201034666A (en) 2008-12-22 2010-10-01 Schering Corp Gamma secretase modulators
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
US8703954B2 (en) 2009-02-26 2014-04-22 Eisai R&D Management Co., Ltd. Salt of tetrahydrotriazolopyridine derivative and crystal thereof
TW201035101A (en) * 2009-02-26 2010-10-01 Eisai R&D Man Co Ltd Nitrogen-containing fused heterocyclic compound
JP2012051807A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
JP2012051805A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd テトラヒドロトリアゾロピリジン誘導体の製造方法
JP2012121809A (ja) * 2009-02-26 2012-06-28 Eisai R & D Management Co Ltd 多環式化合物の製造法およびその中間体
CA2767764A1 (en) 2009-07-13 2011-01-20 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8871760B2 (en) * 2009-09-21 2014-10-28 Roche Palo Alto Llc [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
US9145399B2 (en) * 2010-01-15 2015-09-29 Janssen Pharmaceuticals, Inc. Substituted bicyclic triazole derivatives as gamma secretase modulators
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
WO2011109799A1 (en) 2010-03-05 2011-09-09 Karyopharm Therapeutics, Inc. Nuclear transport modulatiors and uses thereof
KR20130139895A (ko) * 2010-09-02 2013-12-23 다케다 야쿠힌 고교 가부시키가이샤 경도인지 장애의 치료 또는 예방용 융합 트리아졸
JP2014012641A (ja) * 2010-10-29 2014-01-23 Dainippon Sumitomo Pharma Co Ltd 新規ピリジン誘導体
AU2012207565B2 (en) * 2011-01-17 2016-04-07 Karyopharm Therapeutics Inc. Olefin containing nuclear transport modulators and uses thereof
GEP201706616B (en) 2011-07-29 2017-02-10 Karyopharm Therapeutics Inc Hydrazide containing nuclear transport modulators and usage thereof
BR112014001933A2 (pt) 2011-07-29 2017-02-21 Karyopharm Therapeutics Inc moduladores de transporte nuclear e usos dos mesmos
WO2013055793A1 (en) * 2011-10-12 2013-04-18 University Of Pittsburg-Of The Commonwealth System Of Higher Education Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
WO2013170068A2 (en) 2012-05-09 2013-11-14 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EA027242B1 (ru) 2012-05-16 2017-07-31 Янссен Фармасьютикалз, Инк. ЗАМЕЩЕННЫЕ 3,4-ДИГИДРО-2H-ПИРИДО[1,2-a]ПИРАЗИН-1,6-ДИОНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ ДЛЯ ЛЕЧЕНИЯ (В ТОМ ЧИСЛЕ) БОЛЕЗНИ АЛЬЦГЕЙМЕРА
EP2687528A1 (en) * 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
ES2608356T3 (es) 2012-12-20 2017-04-10 Janssen Pharmaceutica Nv Novedosos derivados tricíclicos de 3,4-dihidro-2H-pirido[1,2-a]pirazin-1,6-diona como moduladores de la secretasa gamma
EP2945944B1 (en) 2013-01-17 2016-11-09 Janssen Pharmaceutica, N.V. Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
US10202366B2 (en) 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
CA2915365C (en) 2013-06-21 2022-08-16 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
US10882834B2 (en) 2013-09-20 2021-01-05 University of Pittsburgh—of the Commonwealth System of Higher Education Compounds for treating prostate cancer
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
MA40254B1 (fr) 2014-08-15 2022-09-30 Karyopharm Therapeutics Inc Polymorphes du selinexor
MA43529A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
MA43530A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
SG11201806383TA (en) * 2016-02-23 2018-09-27 Pfizer 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0400570A3 (en) * 2000-12-04 2004-09-28 Hoffmann La Roche Phenylethenyl or phenylethinyl heteroaril derivatives as glutamate receptor antagonists, their use, process for their preparation and pharmaceutical compositions containing them
CA2514363A1 (en) * 2003-02-12 2004-08-26 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
EP1730118A1 (en) * 2004-02-12 2006-12-13 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
TWI335816B (en) * 2004-05-26 2011-01-11 Eisai R&D Man Co Ltd Cinnamide compound

Also Published As

Publication number Publication date
GEP20115139B (en) 2011-01-10
CA2643796A1 (en) 2007-09-13
CY1112767T1 (el) 2016-02-10
HK1128085A1 (en) 2009-10-16
EP1992618A1 (en) 2008-11-19
IL193770A (en) 2012-10-31
HK1122027A1 (en) 2009-05-08
PL1992618T3 (pl) 2012-06-29
AU2007223158B2 (en) 2012-04-12
HRP20120174T1 (hr) 2012-03-31
AU2007223158A1 (en) 2007-09-13
KR101464651B1 (ko) 2014-11-24
AR059955A1 (es) 2008-05-14
MX2008011221A (es) 2008-09-11
IL193770A0 (en) 2009-05-04
EA016464B1 (ru) 2012-05-30
EP1992618B1 (en) 2012-01-18
EP1992618A4 (en) 2010-11-10
MA30268B1 (fr) 2009-03-02
EA200870336A1 (ru) 2009-02-27
WO2007102580A1 (ja) 2007-09-13
KR20080108481A (ko) 2008-12-15

Similar Documents

Publication Publication Date Title
HN2008001374A (es) Compuestos de cinamida policiclicos
UY32045A (es) Compuesto amida
PA8850801A1 (es) Compuestos útiles para inhibir chk1
GT201200164A (es) "nuevos compuestos de espiropiperidina"
GT201400111A (es) Triazolopiridinas sustituidas
UY31050A1 (es) Antagonistas de trpv1 y usos de los mismos
AR077629A1 (es) Mimetico de smac
CR20110092A (es) Nuevos compuestos utiles para el tratamiento de enfermedades degenerativas e inflamatorias
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
ECSP11010880A (es) Compuestos orgánicos
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
ECSP088625A (es) Compuestos para el tratamiento de trastornos inflamatorios
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
UY32820A (es) Composiciones dermatologicas de antagonistas del receptor dp2
ECSP11011411A (es) Derivados de prolina como inhibidores de catepsina
SV2010003777A (es) Compuestos organicos
CL2012002706A1 (es) Composicion farmaceutica termogelificante estabilizada compuesta por anestesicos locales con un ph de al menos el pka de dichos anestesicos, que comprende a) la forma basica de uno o mas anestesicos de tipo amida, b) 10 a 30% de un aceite de ricino polioxietilado, y c) al menos 15% de uno o mas tensioactivos; y su metodo de preparacion.
DOP2006000170A (es) Nuevos derivados de espirocromanona
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
GT200900062A (es) Nuevos compuestos de diosmetina, un proceso para su preparacion y las composiciones farmaceuticas que los contienen
MX345032B (es) Antagonistas del receptor ep4 para el tratamiento de cáncer.
CL2008002826A1 (es) Compuestos derivados de pirimidina alquiltio sustituidas, antagonista crth2; composicion farmaceutica que comprende a dicho compuestos; y uso para tratar una enfermedad alergica, asma, dermatitis atopica, psoriasis, colitis ulcerantes, sinusitis, leucemia basofilica, entre otras.
CL2011002463A1 (es) Compuestos heterociclicos, agonistas del receptor de glucocorticoide; composicion farmaceutica que comprende a dicho compuesto; composicion farmaceutica; kit farmaceutico; uso del compuesto para tratar el asma, enfermedad pulmonar obstructiva cronica o rinitis alergica.